Merck considering takeover of Cubist Pharmaceuticals

posted by Phill Allen

December, 08th, 2014

Company News

American drug giant Merck is reportedly eying up a possible acquisition of the biopharmaceuticals company Cubist Pharmaceuticals.
Merck considering takeover of Cubist Pharmaceuticals
The deal, according to the New York Times, could be announced as early as next week. Merck could pay around $100 a share in a move which would value the US antibiotics maker in the range of $7.5 billion.
Cubist, which makes drugs to treat dangerous bacteria and superbugs in the developing world, has seen its share value nearly double over the last two years.
Should the deal go through it would mark the latest in a long line of multibillion-dollar pharmaceutical mergers and acquisitions.
Merck, one of America’s largest makers of vaccines, prescription products and oncology treatments, has a market value in excess of $174 billion.

Related reading:

TAGS: Cubist Pharmaceuticals, Merck, Pharmaceutical company,


Avatar photo


Phill Allen

Managing Director

An in and outside the (bioprocess) box thinker, fluid management specialist Phill knows a thing or two about keeping pharma liquid logistics flowing.

<strong>How ALLpaQ Saved Christmas</strong>
Company News

How ALLpaQ Saved Christmas

As Sir Noddy of Holder once said: “It’s Chriiiistmaaaas!” Oh, you’ve noticed. While some retailers may have been trying to […]

Dec 02nd, 2022